Granted Patent
B2
US 10,329,270 · App. 15/029,420 · Granted Jun 25, 2019
Heteroaryl compounds as BTK inhibitors and uses thereof
Inventors:
Hui Qiu (Acton, MA); Richard D. Caldwell (Melrose, MA); Constantin Neagu (Belmont, MA); Igor Mochalkin (San Diego, CA); Lesley Liu-Bujalski (Bedford, MA); Reinaldo Jones (Lowell, MA); Devon Tate (Bedford, MA); Theresa L. Johnson (Salem, MA); Anna Gardberg (Arlington, MA)
Assignee:
Merck Patent GmbH
C07D401/04A61K9/0019A61K9/0043A61K9/0048A61K9/0078A61K9/02A61K9/06A61K9/08A61K9/1688A61K9/19A61K9/2018A61K9/2059A61K9/286A61K9/2826A61K47/06A61K47/186C07D213/81C07D213/82C07D239/47C07D239/48C07D401/12C07D401/14C07D403/04C07D403/12C07D405/04C07D405/14C07D407/04C07D409/04C07D413/04C07D413/06C07D413/14C07D451/02C07D471/08C07D487/04C07D487/08C07D487/10C07D495/04C07F5/022
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to pyridine, pyrimidine, pyrazine, and pyridazine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
Claims (8)
1. A compound selected from the group consisting of
and
a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition, comprising:
a compound of claim 1 , and
a pharmaceutically acceptable adjuvant, carrier, or vehicle.
3. A method for inhibiting BTK, or a mutant thereof, activity in a patient in need thereof or in a biological sample, comprising:
administering to said patient or contacting said biological sample with a compound of claim 1 or a physiologically acceptable salt thereof.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 20, 2016
From: QIU, HUI; CALDWELL, RICHARD; NEAGU, CONSTANTIN; MOCHALKIN, IGOR; LIU-BUJALSKI, LESLEY; JONES, REINALDO; TATE, DEVON; JOHNSON, THERESA; GARDBERG, ANNA
To: MERCK PATENT GMBH
Reel/Frame 038958/0028 →
Continuity (2)
Provisional Application
61893613
· Oct 21, 2013